Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary.
Osteoporosis is recognized as a major public health problem worldwide and in Taiwan. However, many patients with osteoporotic fractures do not receive appropriate assessments or treatments. This guideline, proposed by the Taiwanese Osteoporosis Association, is to serve as a quick reference for healthcare providers to improve the assessment of osteoporosis and development of optimal strategies for osteoporotic management in Taiwan. To review and update osteoporosis management, the guideline is constituted with Taiwan-specific osteoporosis epidemiological data, medication protocols, and the 10-year FRAX(®). The guideline is based on evidence-based medicine and public health considerations. Recommendations are not limited to the reimbursement regulations permitted by the National Health Insurance of Taiwan.
Division of Endocrinology and Metabolism, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
Jawl-Shan
JS
Hwang
Ding-Cheng
DC
Chan
Jung-Fu
JF
Chen
Tien-Tsai
TT
Cheng
Chih-Hsing
CH
Wu
Yung-Kuei
YK
Soong
Keh-Sung
KS
Tsai
Rong-Sen
RS
Yang
D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects; D006801:Humans; D010024:Osteoporosis / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000517:prevention & control* / Q000628:therapy*; D017410:Practice Guidelines as Topic; D011634:Public Health; D011859:Radiography; D013624:Taiwan
D050071:Bone Density Conservation Agents